Protalix BioTherapeutics Inc (AMEX: PLX) Gains 18.57% And Its 11.88% Stock Volatility Is Bewildering

Protalix BioTherapeutics Inc (AMEX:PLX) does about 191.02K shares in volume on a normal day but saw 1783235 shares change hands in the recent trading day. The company now has a market cap of 121.37M USD. Its current market price is $1.66, marking an increase of 18.57% compared to the previous close of $1.40. The 52 week high reached by this stock is $1.90 whilst the lowest price level in 52 weeks is $0.82.

Protalix BioTherapeutics Inc (PLX) has a 20-day trading average at $1.2215 and the current price is -12.63% off the 52-week high compared with 102.09% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.1264 and its 200-day simple moving average is $1.1818. If we look at the stock’s price movements over the week, volatility stands at 11.88%, which decreases to 6.44% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 76.90 to suggest the stock is overbought.

The consensus objective for the share price is $14.00, suggesting that the stock has a potential upside of 88.14% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 08, 2020 when H.C. Wainwright reiterated the stock to “Buy” and issued a price target of between $3 and $11. Rodman & Renshaw initiated its price target at $3.50.

The current price level is 35.90%, 47.37%, and 40.47% away from its SMA20, SMA50, and SMA200 respectively, with the PLX price moving below the 50-day SMA on current market day. Protalix BioTherapeutics Inc (PLX) stock is up 38.33% over the week and 52.29% over the past month. Its price is -6.74% year-to-date and 19.42% over the past year.

To reach the target analysts have set, the stock logically needs to grow 88.14 percent from here.

The company has a return on investment of -26.24% and return on equity of -27.18%. The forward price to earnings ratio is 2.63. The beta has a value of 0.64. Price to book ratio is 3.77 and price to sales ratio is 2.66.